KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced today, October 6, 2025, that it has released new data from its KONFIDENT and KONFIDENT‑S studies of EKTERLY (sebetralstat). The data were presented at the 20th German Allergy Congress in Düsseldorf, Germany, which ran from October 2 to October 4, 2025.
Across multiple ePoster presentations, EKTERLY demonstrated the ability to rapidly halt the progression of hereditary angioedema (HAE) attacks, delivering rapid symptom relief. The findings reinforce EKTERLY’s position as the first and only oral on‑demand therapy for HAE and support its continued commercial rollout.
The announcement marks a significant milestone in KalVista’s product development pipeline, providing fresh clinical evidence that may strengthen payer and provider confidence in EKTERLY. The new data also underscore the company’s commitment to advancing oral therapies for rare diseases and could accelerate market adoption in Europe and beyond.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.